Want to see AU:AT1 full AI Analyst Report?
Top Page
Atomo Diagnostics Ltd.
(Sydney:AT1)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.02
▼(-5.00% Downside)
Action:Reiterated
Date:09/06/26
The score is primarily constrained by weak financial quality—ongoing losses, negative gross margin in FY2026, and persistent negative operating/free cash flow—despite strong FY2026 revenue growth and a low-debt balance sheet. Technicals also weigh on the score as the price remains below longer-term moving averages with negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Low Leverage
Minimal financial leverage (debt/equity ~0.03) gives Atomo durable financial flexibility versus highly leveraged peers. With low interest burden the company can prioritize product development, absorb near-term losses, and pursue partnerships or manufacturing scale without immediate refinancing pressure.
Negative Factors
Declining Revenue
Two-digit revenue decline signals structural demand or commercialization challenges for Atomo’s products. Persistent top-line contraction undermines scale benefits, slows payback on R&D and customer onboarding, and makes it harder to leverage fixed-cost manufacturing to restore profitability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal financial leverage (debt/equity ~0.03) gives Atomo durable financial flexibility versus highly leveraged peers. With low interest burden the company can prioritize product development, absorb near-term losses, and pursue partnerships or manufacturing scale without immediate refinancing pressure.
Read all positive factors
Atomo Diagnostics Ltd. (AT1) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$17.15M
Dividend YieldN/A
Average Volume (3M)500.22K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth40.65%
EPS Growth45.45%
CountryAU
Employees85
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume172,195
30 Day Avg. Volume500,217
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.82
Price to Sales (P/S)2.64
P/FCF Ratio-4.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.96M
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Company Description
Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various ap...
How the Company Makes Money
Atomo Diagnostics makes money primarily by supplying its proprietary rapid test device platforms and associated components to third parties that manufacture and sell completed diagnostic tests. Revenue is generated through sales of physical produc...
Atomo Diagnostics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.33M | 3.79M | 4.09M | 2.54M | 12.34M |
| Gross Profit | -2.43M | 1.79M | 1.44M | -6.08M | -1.85M |
| EBITDA | -4.26M | -4.69M | -6.12M | -9.00M | -4.72M |
| Net Income | -3.51M | -4.97M | -6.85M | -9.96M | -5.71M |
Balance Sheet | |||||
| Total Assets | 10.83M | 9.28M | 11.38M | 16.47M | 26.62M |
| Cash, Cash Equivalents and Short-Term Investments | 3.71M | 3.22M | 3.69M | 6.47M | 12.97M |
| Total Debt | 373.08K | 185.10K | 141.19K | 254.88K | 340.81K |
| Total Liabilities | 3.12M | 2.30M | 1.29M | 1.68M | 1.81M |
| Stockholders Equity | 7.71M | 6.98M | 10.08M | 14.79M | 24.81M |
Cash Flow | |||||
| Free Cash Flow | -3.40M | -1.99M | -4.70M | -6.25M | -5.11M |
| Operating Cash Flow | -3.37M | -1.96M | -4.69M | -5.85M | -2.81M |
| Investing Cash Flow | -35.32K | -33.89K | -16.08K | -401.28K | -2.31M |
| Financing Cash Flow | 3.81M | 1.46M | 1.87M | -170.75K | 17.61K |
Atomo Diagnostics Ltd. Technical Analysis
Negative
0.02
Price Trends
0.02
Positive
0.02
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
0.46
Positive
250.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AT1, the sentiment is Negative. The current price of 0.02 is equal to the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 0.46 is Positive, neither overbought nor oversold. The STOCH value of 250.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AT1.
Atomo Diagnostics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$49.94M | 227.27 | 0.93% | ― | 18.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$174.76M | -20.59 | -46.84% | ― | ― | 20.40% | |
45 Neutral | AU$17.15M | -4.52 | -48.97% | ― | 40.65% | 45.45% | |
45 Neutral | AU$20.14M | -0.47 | -259.31% | ― | 14.85% | -1.74% | |
42 Neutral | AU$65.38M | -3.25 | -62.14% | 0.64% | 12.05% | -31.71% | |
40 Underperform | AU$16.55M | -1.54 | -188.06% | ― | 15.58% | 37.17% |
* Healthcare Sector Average
AU:AT1
Atomo Diagnostics Ltd.
0.02
>-0.01
-5.00%
AU:CMP
Compumedics Limited
0.25
-0.07
-20.63%
AU:IPD
Impedimed Limited
0.01
-0.03
-65.00%
AU:CYC
Cyclopharm Limited
0.52
-0.36
-40.91%
AU:MX1
Micro-X Ltd.
0.02
-0.07
-75.56%
AU:EMV
EMvision Medical Devices Ltd.
1.88
-0.10
-5.05%
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics Files Appendix 4G, Confirms Governance Compliance
Aug 31, 2026
Atomo Diagnostics Limited, an ASX-listed medical diagnostics group, operates in the healthcare sector with a focus on rapid testing solutions and structured corporate governance. The company maintains a board charter and formalised executive arran...
Atomo Diagnostics Issues Cautious FY26 Results Overview
Aug 31, 2026
Atomo Diagnostics has released an overview of its FY26 results, presented as a high‑level information update for investors rather than a detailed financial report. The document emphasises that the material is general in nature, should not be...
Atomo Diagnostics Lifts Revenue and Narrows Annual Loss
Aug 31, 2026
Atomo Diagnostics reported a 41% increase in revenue from ordinary activities to AUD 5.33 million for the year to 30 June 2026, while narrowing its after-tax loss by 29% to AUD 3.51 million. Basic and diluted loss per share improved to 0.425 cents...
Atomo Diagnostics Discloses Director John Kelly’s Exit and Ongoing Shareholding
Aug 19, 2026
Atomo Diagnostics Ltd. has announced that director John Kelly ceased to be a member of the board on 19 August 2026, formalising the change in governance disclosed to the ASX. The notice confirms his substantial direct and indirect shareholdings an...
Atomo Diagnostics Boosts Revenue and Expands Test Portfolio in Q4 FY26
Jul 22, 2026
Atomo Diagnostics reported unaudited FY26 revenue of $5.3 million, up 40% on the prior year, with Q4 revenue of $2.3 million and cash receipts of $3.8 million. The company ended June with $3.7 million in cash and no debt, while securing more than ...
Atomo Diagnostics Trims Option Overhang as Unexercised Securities Lapse
Jul 1, 2026
Atomo Diagnostics has updated the market on changes to its capital structure, notifying the cessation of certain options that formed part of its previously issued securities. The company reported that a total of 533,334 options expired unexercised...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.